DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2016/0166687 A1 Schultz Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2016/0166687 A1 Schultz Et Al US 2016O166687A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0166687 A1 Schultz et al. (43) Pub. Date: Jun. 16, 2016 (54) DIRECTED DIFFERENTATION OF Publication Classification OLGODENIDROCYTE PRECURSORCELLS TO A MYELINATING CELL FATE (51) Int. Cl. A 6LX39/395 (2006.01) (71) Applicants: The Scripps Research Institute, La A613 L/35 (2006.01) Jolla, CA (US); IRM LLC, Hamilton A638/2I (2006.01) (BM) A63/545 (2006.01) A63/37 (2006.01) (72) Inventors: Peter Schultz, La Jolla, CA (US); Luke A613 L/439 (2006.01) Lairson, San Diego, CA (US); Vishal A613 L/40 (2006.01) Deshmukh, La Jolla, CA (US); Costas (52) U.S. Cl. Lyssiotis, Boston, MA (US) CPC ........... A61K.39/3955 (2013.01); A61K3I/439 (2013.01); A61 K3I/135 (2013.01); A61 K 31/40 (2013.01); A61 K31/5415 (2013.01); (21) Appl. No.: 14/973,105 A6 IK3I/137 (2013.01); A61 K38/215 (2013.01) (22) Filed: Dec. 17, 2015 (57) ABSTRACT The present invention provides methods of inducing differ entiation of oligodendrocyte progenitor cells to a mature Related U.S. Application Data myelinating cell fate with a neurotransmitter receptor modu lating agent. The present invention also provides methods of (62) Division of application No. 13/985,342, filed on Oct. stimulating increased myelination in a Subject in need thereof 18, 2013, filed as application No. PCT/US2012/ by administering said neurotransmitter receptor modulating 025712 on Feb. 17, 2012. agent. Methods of treating a subject having a demyelinating (60) Provisional application No. 61/444,666, filed on Feb. disease using a neurotransmitter receptor modulating agent 18, 2011. are also provided. Patent Application Publication Jun. 16, 2016 Sheet 1 of 52 US 2016/O166687 A1 Fig. A A. y as ---o---&e - ...? - (C. 1- os-s s is - -w N les d ser:Sties ECsxf3 : - Y - - AN ls-N- s-S s f t lass-s-CJC-s--as-SE a^----->-9s-s-s- Y- asso; st - S. Saietara Esox e ass-Ya-Y^N S3? SS- Ys- s^\ or say 33S: Csex 88) s Patent Application Publication Jun. 16, 2016 Sheet 2 of 52 US 2016/O166687 A1 Fig. 1 B-C B. sexes eastific - GBR 12935 rte Trifuroperazine -- Carbetapentane/ 3 or Benztropirie A £3. 328i a & S. o compound ut C. 83 x. Pot&scy : 8. Patent Application Publication Jun. 16, 2016 Sheet 3 of 52 US 2016/O166687 A1 Fig. 2A VS 3 3: Benzatropine 4: Carbapentarie 5: Clemastine s: BR3s : Sarreteroi Patent Application Publication Jun. 16, 2016 Sheet 4 of 52 US 2016/O166687 A1 Fig. 2B-C MBP or PCR fs aaaaaaassassessex sessssssssssex MOG qrTPCR ' Patent Application Publication Jun. 16, 2016 Sheet 5 of 52 US 2016/O166687 A1 Fig. 3 S. Eenza tropiirig Certasting Carbagentaris rifoperazine Sainstger 3. s Patent Application Publication Jun. 16, 2016 Sheet 6 of 52 US 2016/O166687 A1 Patent Application Publication Jun. 16, 2016 Sheet 7 of 52 US 2016/O166687 A1 Fig. 5A Mycophenoiate S: view 8::::8 2. l rurvyce::::::::giate 2. s m 3. c X s : 8 : - X - ; ; ; ; i. 8,s : Y e 8: M 8 is is a 3 is is 8:232; asks: 33 days Patent Application Publication Jun. 16, 2016 Sheet 8 of 52 US 2016/O166687 A1 Fig. 5B-C , Berizatropine 3. are feice 3: --8es:stropis: 3. 8S. B.S 38 8 : 2: 3 x 3 8 8 3 & 1 : 3 x 38 88233:32:32:3S28.238883 bays Berizatropine + Mycophenotate C. $8. view Veiicie 83 w- 88:a::pin83-8:ysogies: is 2.8 raw -- s s & : & f is: e ar -- a s 8 see 8. s 3 s : 8 8 & St: 31:383 & 832 &23 &2S288883 says Patent Application Publication Jun. 16, 2016 Sheet 9 of 52 US 2016/O166687 A1 Fig. 5D-E , rifluoperazine 3.8 were fe:::::::: waii:iog&razi& 3. S. : S. - i. 88. 3 : R 3 & 8 & 8 3 - 3 3 SS 8 SR32 &33.823 & 288383 ays E. rifitioperazine + Mycopheridiate 38 area ixticia 28 re-fiftgesperagine-8-ycopiesotate 3. 8 s sk t & 8S 88: 3 a 3 & 8 & 2 8 & St 323 & 33 8: 8832 & 23 23828 2:28:28 383; says Patent Application Publication Jun. 16, 2016 Sheet 10 of 52 US 2016/0166687 A1 Fig. 6A-B A. w8 20- ox & g15... xx x CabapentaréAX. e- x- Beizatioisie | glo- wer Safete:{: N. x - o Conc. (ab3880i is 3. also Sametro, GBR12935, , , , Trifluoperazine, 3. Benztropine, Carbapentane, Ciennastine Patent Application Publication Jun. 16, 2016 Sheet 11 of 52 US 2016/O166687 A1 Fig. 7-i-C A. Berztragine is is: 88:tragie C. Cartacitoi (3:38 Cart:8::it: ,8. i carbacio; 4,7uki is soil 88xtropise 3.3ai) Patent Application Publication Jun. 16, 2016 Sheet 12 of 52 US 2016/O166687 A1 Fig. 8A-B A. case feise .x. Benxtropine herapeutic * Bextropine Prophylactic : -- FTY720 Therapeutic -x.interferon- herapeutic 3. s 2ogo. Ovehicle s: Bextrepine p-905 tooo soo x S Patent Application Publication Jun. 16, 2016 Sheet 13 of 52 US 2016/O166687 A1 Fig. 8C Patent Application Publication Jun. 16, 2016 Sheet 14 of 52 US 2016/O166687 A1 Ciprixote ost Ciprixote iftistiawa :::::K 88k 8& 3 &:::::: co grey sess co-st vehisie &extrepite seates Patent Application Publication Jun. 16, 2016 Sheet 15 of 52 US 2016/O166687 A1 Fig. (A-B A. : see fei: - 8 FY720 mg/kg 4.0 * BA 2.5mg/kg : "*" FTY720 irrigkg - : 3.5 8A 2.5 kg & 3.0 8 2.5- a 2.8 s s: : 3. 0.0 ex-rm: ''''''''''''''''''' -----------------------... s : s 3ys fee .x. F8-3 (0. -x Bk 3.3 gig -x-x- E - 882.sg/kg w - X: s ' x Yw- .xx 8:8 - 8& o, obsessm--------------------------------- s · s 3. 3y & Patent Application Publication Jun. 16, 2016 Sheet 16 of 52 US 2016/O166687 A1 Fig. 10C-D easo fee wx FY720 O. mg/kg -- FTY720 mgkg * BA 2.5gkg 8-8-8-8-8-8-8-8-8-- --------------------------------------------------------------------, s 's x 3. ays 8. : ex feixie x FN-3 300 -x FN-3 (i. * 8A2. Singkg .5 0.0 esses ormer : s s : 3. k says Patent Application Publication Jun. 16, 2016 Sheet 17 of 52 US 2016/O166687 A1 Fig. 10E-F mix fecies 4.0. « FY720 mg/kg x Y23 ... gkg 883.Stigkg o,0s sex5 circrto is 20 as 3e says F. xx feiseik x F-8 (388 x F8-380 s 8 - 8x----------------------------------------- ------------------- ---. s s 28 3: 3ys Patent Application Publication Jun. 16, 2016 Sheet 18 of 52 US 2016/O166687 A1 Fig. 1 (A-B 3883: ar. ^ Styxxic hier888 8x & Oligocencirocyte Patent Application Publication Jun. 16, 2016 Sheet 19 of 52 US 2016/O166687 A1 Fig. 2A-B are 88tatropite Ecse 358 & 8. 8.33: 383 . Conc. (i. 88::::::::::::8 8.3: 8883xxxxxx 8.8 ::::: :yrexies sixx xxx: { Patent Application Publication Jun. 16, 2016 Sheet 20 of 52 US 2016/O166687 A1 Fig. 3 B Atti Patent Application Publication Jun. 16, 2016 Sheet 21 of 52 US 2016/O166687 A1 Fig. 14 tyroix: 3883 88:::::::: x38x3:38 Patent Application Publication Jun. 16, 2016 Sheet 22 of 52 US 2016/O166687 A1 Patent Application Publication Jun. 16, 2016 Sheet 23 of 52 US 2016/O166687 A1 A. Benztropied hyroid erroref OCS SO S. T. Apod T-s""or "".2" Enpp6 .a. 11.58; S.06 -----------------Mag. 0.10.3.70...4.64. Mbp .5 --> 3.88 3.55 ... Mobp . .0.46 2.04 87.70 . .wog. ... 0.2 ... .88.i.28.23. Oig .98 O.97 O.75 Pip G.17 97 2.33 Prip 1. 0.44 3.3a 3. Tpd52 24 2.28 2. S (CfS Berztropinei hyroid Hormonel S S. Patent Application Publication Jun. 16, 2016 Sheet 24 of 52 US 2016/O166687 A1 Fig. 7A-B A. Day 6 lay ::::::::::::: & Day 1 ::::::::::::: & say 3 d :::::::::::: lay d 8:33:38& 8:3 say $. *:::::iy 88.8 xx IBEY., od ORY.S. on Patent Application Publication Jun. 16, 2016 Sheet 25 of 52 US 2016/O166687 A1 Fig. 17C-D Berztropire .5 Mt Day 0 ay Day 2 Day 3 lay 4 lay 5 i Betztropire .5u Day 3 ay 4 ay 5 Day 8 Patent Application Publication Jun. 16, 2016 Sheet 26 of 52 US 2016/O166687 A1 Fig. 18 S. Casaki is...} Bextropire (2.3a;-- $3.338 &S Patent Application Publication Jun. 16, 2016 Sheet 27 of 52 US 2016/O166687 A1 Fig. 194-B A. 8. 8 36 w x 8. s: 2 Betztropite (.8 it Histamine ii.7 uti) is&ies .38: Histantire (3 tit} B. i Benetrapine it.8 til Rif (s.7 as: 8, 8. hit 8 (0 tit} Patent Application Publication Jun. 16, 2016 Sheet 28 of 52 US 2016/O166687 A1 Fig. 204-B s i Benztropine it.8 it Quiripiroie (4.7 at tipirote (0.8 .it Quinpiroie to it i s Benztropine (.8 it taiaperidad (4.7 aii iaixperide: {{.{ ai: Hairsperidol (g at Patent Application Publication Jun. 16, 2016 Sheet 29 of 52 US 2016/O166687 A1 Fig. 21 -- oxyxyri - EC 8.8 six x &t epise i-Ecs: s. 38 x igratropi: i-Ecs: S.8 s. w topiyerine {-EC, 8.83 :: Sc{{{xiasise {^E{s: 3. 38: o, o os ooo cote. & Recepte Rii Recepto: i3 Reeete: Patent Application Publication Jun. 16, 2016 Sheet 30 of 52 US 2016/O166687 A1 Fig. 23A A. *:::::::ces : s ::: 33 8. *:::ssion p38xtapK esta p38 is: ph:3spher &ist faste: 8xt 88sho 32f& xiàK exai 83 f$8 wArK. Piaspx E8 issi E3 Patent Application Publication Jun.
Load more

Recommended publications
  • TABLE 1 Studies of Antagonist Activity in Constitutively Active
    TABLE 1 Studies of antagonist activity in constitutively active receptors systems shown to demonstrate inverse agonism for at least one ligand Targets are natural Gs and constitutively active mutants (CAM) of GPCRs. Of 380 antagonists, 85% of the ligands demonstrate inverse agonism. Receptor Neutral Antagonist Inverse Agonist Reference Human β2-adrenergic Dichloroisoproterenol, pindolol, labetolol, timolol, Chidiac et al., 1996; Azzi et alprenolol, propranolol, ICI 118,551, cyanopindolol al., 2001 Turkey erythrocyte β-adrenergic Propranolol, pindolol Gotze et al., 1994 Human β2-adrenergic (CAM) Propranolol Betaxolol, ICI 118,551, sotalol, timolol Samama et al., 1994; Stevens and Milligan, 1998 Human/guinea pig β1-adrenergic Atenolol, propranolol Mewes et al., 1993 Human β1-adrenergic Carvedilol CGP20712A, metoprolol, bisoprolol Engelhardt et al., 2001 Rat α2D-adrenergic Rauwolscine, yohimbine, WB 4101, idazoxan, Tian et al., 1994 phentolamine, Human α2A-adrenergic Napthazoline, Rauwolscine, idazoxan, altipamezole, levomedetomidine, Jansson et al., 1998; Pauwels MPV-2088 (–)RX811059, RX 831003 et al., 2002 Human α2C-adrenergic RX821002, yohimbine Cayla et al., 1999 Human α2D-adrenergic Prazosin McCune et al., 2000 Rat α2-adrenoceptor MK912 RX821002 Murrin et al., 2000 Porcine α2A adrenoceptor (CAM- Idazoxan Rauwolscine, yohimbine, RX821002, MK912, Wade et al., 2001 T373K) phentolamine Human α2A-adrenoceptor (CAM) Dexefaroxan, (+)RX811059, (–)RX811059, RS15385, yohimbine, Pauwels et al., 2000 atipamezole fluparoxan, WB 4101 Hamster α1B-adrenergic
    [Show full text]
  • Arecoline Promotes Migration of A549 Lung Cancer Cells Through Activating the EGFR/Src/FAK Pathway
    toxins Article Arecoline Promotes Migration of A549 Lung Cancer Cells through Activating the EGFR/Src/FAK Pathway Chih-Hsiang Chang 1,†, Mei-Chih Chen 2,3,†, Te-Huan Chiu 1 , Yu-Hsuan Li 1, Wan-Chen Yu 1, Wan-Ling Liao 1, Muhammet Oner 1, Chang-Tze Ricky Yu 4, Chun-Chi Wu 5, Tsung-Ying Yang 6, Chieh-Lin Jerry Teng 7, Kun-Yuan Chiu 8, Kun-Chien Chen 6, Hsin-Yi Wang 9, Chia-Herng Yue 10, Chih-Ho Lai 11 , Jer-Tsong Hsieh 12 and Ho Lin 1,13,14,* 1 Department of Life Sciences, National Chung Hsing University, Taichung 40227, Taiwan; [email protected] (C.-H.C.); [email protected] (T.-H.C.); [email protected] (Y.-H.L.); [email protected] (W.-C.Y.); [email protected] (W.-L.L.); [email protected] (M.O.) 2 Medical Center for Exosomes and Mitochondria Related Diseases, China Medical University Hospital, Taichung 40447, Taiwan; [email protected] 3 Department of Nursing, Asia University, Taichung 41345, Taiwan 4 Department of Applied Chemistry, National Chi Nan University, Nantou 54561, Taiwan; [email protected] 5 Institute of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan; [email protected] 6 Division of Chest Medicine, Taichung Veterans General Hospital, Taichung 40705, Taiwan; [email protected] (T.-Y.Y.); [email protected] (K.-C.C.) 7 Division of Hematology/Medical Oncology, Taichung Veterans General Hospital, Taichung 40705, Taiwan; [email protected] 8 Division of Urology, Taichung Veterans General Hospital, Taichung 40705, Taiwan; [email protected] 9 Department of Nuclear Medicine, Taichung
    [Show full text]
  • Drug Class Review Beta Adrenergic Blockers
    Drug Class Review Beta Adrenergic Blockers Final Report Update 4 July 2009 Update 3: September 2007 Update 2: May 2005 Update 1: September 2004 Original Report: September 2003 The literature on this topic is scanned periodically. The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use, or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Mark Helfand, MD, MPH Kim Peterson, MS Vivian Christensen, PhD Tracy Dana, MLS Sujata Thakurta, MPA:HA Drug Effectiveness Review Project Marian McDonagh, PharmD, Principal Investigator Oregon Evidence-based Practice Center Mark Helfand, MD, MPH, Director Oregon Health & Science University Copyright © 2009 by Oregon Health & Science University Portland, Oregon 97239. All rights reserved. Final Report Update 4 Drug Effectiveness Review Project TABLE OF CONTENTS INTRODUCTION .......................................................................................................................... 6 Purpose and Limitations of Evidence Reports........................................................................................ 8 Scope and Key Questions .................................................................................................................... 10 METHODS.................................................................................................................................
    [Show full text]
  • From Inverse Agonism to 'Paradoxical Pharmacology' Richard A
    International Congress Series 1249 (2003) 27-37 From inverse agonism to 'Paradoxical Pharmacology' Richard A. Bond*, Kenda L.J. Evans, Zsirzsanna Callaerts-Vegh Department of Pharmacological and Pharmaceutical Sciences, University of Houston, 521 Science and Research Bldg 2, 4800 Caltioun, Houston, TX 77204-5037, USA Received 16 April 2003; accepted 16 April 2003 Abstract The constitutive or spontaneous activity of G protein-coupled receptors (GPCRs) and compounds acting as inverse agonists is a recent but well-established phenomenon. Dozens of receptor subtypes for numerous neurotransmitters and hormones have been shown to posses this property. However, do to the apparently low percentage of receptors in the spontaneously active state, the physiologic relevance of these findings remains questionable. The possibility that the reciprocal nature of the effects of agonists and inverse agonists may extend to cellular signaling is discussed, and that this may account for the beneficial effects of certain p-adrenoceptor inverse agonists in the treatment of heart failure. © 2003 Elsevier Science B.V. All rights reserved. Keywords. Inverse agonism; GPCR; Paradoxical pharmacology 1. Brief history of inverse agonism at G protein-coupled receptors For approximately three-quarters of a century, ligands that interacted with G protein- coupled receptors (GPCRs) were classified either as agonists or antagonists. Receptors were thought to exist in a single quiescent state that could only induce cellular signaling upon agonist binding to the receptor to produce an activated state of the receptor. In this model, antagonists had no cellular signaling ability on their own, but did bind to the receptor and prevented agonists from being able to bind and activate the receptor.
    [Show full text]
  • Upregulation of Peroxisome Proliferator-Activated Receptor-Α And
    Upregulation of peroxisome proliferator-activated receptor-α and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer Chih-Yang Wang, Ying-Jui Chao, Yi-Ling Chen, Tzu-Wen Wang, Nam Nhut Phan, Hui-Ping Hsu, Yan-Shen Shan, Ming-Derg Lai 1 Supplementary Table 1. Demographics and clinical outcomes of five patients with ampullary cancer Time of Tumor Time to Age Differentia survival/ Sex Staging size Morphology Recurrence recurrence Condition (years) tion expired (cm) (months) (months) T2N0, 51 F 211 Polypoid Unknown No -- Survived 193 stage Ib T2N0, 2.41.5 58 F Mixed Good Yes 14 Expired 17 stage Ib 0.6 T3N0, 4.53.5 68 M Polypoid Good No -- Survived 162 stage IIA 1.2 T3N0, 66 M 110.8 Ulcerative Good Yes 64 Expired 227 stage IIA T3N0, 60 M 21.81 Mixed Moderate Yes 5.6 Expired 16.7 stage IIA 2 Supplementary Table 2. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of an ampullary cancer microarray using the Database for Annotation, Visualization and Integrated Discovery (DAVID). This table contains only pathways with p values that ranged 0.0001~0.05. KEGG Pathway p value Genes Pentose and 1.50E-04 UGT1A6, CRYL1, UGT1A8, AKR1B1, UGT2B11, UGT2A3, glucuronate UGT2B10, UGT2B7, XYLB interconversions Drug metabolism 1.63E-04 CYP3A4, XDH, UGT1A6, CYP3A5, CES2, CYP3A7, UGT1A8, NAT2, UGT2B11, DPYD, UGT2A3, UGT2B10, UGT2B7 Maturity-onset 2.43E-04 HNF1A, HNF4A, SLC2A2, PKLR, NEUROD1, HNF4G, diabetes of the PDX1, NR5A2, NKX2-2 young Starch and sucrose 6.03E-04 GBA3, UGT1A6, G6PC, UGT1A8, ENPP3, MGAM, SI, metabolism
    [Show full text]
  • Metabolism and Pharmacokinetics in the Development of New Therapeutics for Cocaine and Opioid Abuse
    University of Mississippi eGrove Electronic Theses and Dissertations Graduate School 2012 Metabolism And Pharmacokinetics In The Development Of New Therapeutics For Cocaine And Opioid Abuse Pradeep Kumar Vuppala University of Mississippi Follow this and additional works at: https://egrove.olemiss.edu/etd Part of the Pharmacy and Pharmaceutical Sciences Commons Recommended Citation Vuppala, Pradeep Kumar, "Metabolism And Pharmacokinetics In The Development Of New Therapeutics For Cocaine And Opioid Abuse" (2012). Electronic Theses and Dissertations. 731. https://egrove.olemiss.edu/etd/731 This Dissertation is brought to you for free and open access by the Graduate School at eGrove. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of eGrove. For more information, please contact [email protected]. METABOLISM AND PHARMACOKINETICS IN THE DEVELOPMENT OF NEW THERAPEUTICS FOR COCAINE AND OPIOID ABUSE A Dissertation presented in partial fulfillment of requirements for the degree of Doctor of Philosophy in Pharmaceutical Sciences in the Department of Pharmaceutics The University of Mississippi by PRADEEP KUMAR VUPPALA April 2012 Copyright © 2012 by Pradeep Kumar Vuppala All rights reserved ABSTRACT Cocaine and opioid abuse are a major public health concern and the cause of significant morbidity and mortality worldwide. The development of effective medication for cocaine and opioid abuse is necessary to reduce the impact of this issue upon the individual and society. The pharmacologic treatment for drug abuse has been based on one of the following strategies: agonist substitution, antagonist treatment, or symptomatic treatment. This dissertation is focused on the role of metabolism and pharmacokinetics in the development of new pharmacotherapies, CM304 (sigma-1 receptor antagonist), mitragynine and 7-hydroxymitragynine (µ-opioid receptor agonists), for the treatment of drug abuse.
    [Show full text]
  • Alpha^ and Beta^Blocking Agents: Pharmacology and Properties
    CURRENT DRUG THERAPY DONALD G. VIDT, MD AND ALAN BAKST, PharmD, EDITORS Alpha^ and beta^blocking agents: pharmacology and properties PROFESSOR B.N.C. PRICHARD • Adrenergic receptors have been separated into alpha and beta groups, which have then been further subdivided. Agents have been developed that block each type of receptor with varying degrees of specificity between the sub-types, leading to differences in pharmacodynamic profile. A more recent innovation has been the development of multiple action beta-blocking drugs, ie, those not only blocking the beta receptors but also posessing a peripheral vasodilator effect that may be due to alpha blockade, beta-2 stimulation, or a vasodilator action independent of either alpha or beta receptors. • INDEX TERMS: ALPHA BLOCKERS; BETA BLOCKERS; HYPERTENSION • CLEVE CLIN ] MED 1991; 58:33 7-350 HE CONCEPT that binding of Rosenblueth suggested that a transmitter released at catecholamines to receptors leads to differ- sympathetic nerve endings produced either inhibitory ing responses was first described by Langley, or excitatory responses as a result of combination with who in 1905 noted that a cell may make sympathin I or sympathin E at the receptor.3 Tmotor or inhibitory substances or both, and that "the The current classification of alpha and beta respon- effect of a nerve impulse depends upon the proportion ses is based on the classic work of Ahlquist,4 who of the two kinds of receptive substance which is af- studied six sympathomimetic amines and found two fected by the impulse."1 In 1906, Dale reported that patterns of reactivity. One group of actions, mediated ergot blocked the excitatory but not the inhibitory ac- by what were termed "alpha receptors," were principally tions of adrenaline.2 In 1933, Cannon and excitatory.
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Us 2018 / 0296525 A1
    UN US 20180296525A1 ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2018/ 0296525 A1 ROIZMAN et al. ( 43 ) Pub . Date: Oct. 18 , 2018 ( 54 ) TREATMENT OF AGE - RELATED MACULAR A61K 38 /1709 ( 2013 .01 ) ; A61K 38 / 1866 DEGENERATION AND OTHER EYE (2013 . 01 ) ; A61K 31/ 40 ( 2013 .01 ) DISEASES WITH ONE OR MORE THERAPEUTIC AGENTS (71 ) Applicant: MacRegen , Inc ., San Jose , CA (US ) (57 ) ABSTRACT ( 72 ) Inventors : Keith ROIZMAN , San Jose , CA (US ) ; The present disclosure provides therapeutic agents for the Martin RUDOLF , Luebeck (DE ) treatment of age - related macular degeneration ( AMD ) and other eye disorders. One or more therapeutic agents can be (21 ) Appl. No .: 15 /910 , 992 used to treat any stages ( including the early , intermediate ( 22 ) Filed : Mar. 2 , 2018 and advance stages ) of AMD , and any phenotypes of AMD , including geographic atrophy ( including non -central GA and Related U . S . Application Data central GA ) and neovascularization ( including types 1 , 2 and 3 NV ) . In certain embodiments , an anti - dyslipidemic agent ( 60 ) Provisional application No . 62/ 467 ,073 , filed on Mar . ( e . g . , an apolipoprotein mimetic and / or a statin ) is used 3 , 2017 . alone to treat or slow the progression of atrophic AMD Publication Classification ( including early AMD and intermediate AMD ) , and / or to (51 ) Int. CI. prevent or delay the onset of AMD , advanced AMD and /or A61K 31/ 366 ( 2006 . 01 ) neovascular AMD . In further embodiments , two or more A61P 27 /02 ( 2006 .01 ) therapeutic agents ( e . g ., any combinations of an anti - dys A61K 9 / 00 ( 2006 . 01 ) lipidemic agent, an antioxidant, an anti- inflammatory agent, A61K 31 / 40 ( 2006 .01 ) a complement inhibitor, a neuroprotector and an anti - angio A61K 45 / 06 ( 2006 .01 ) genic agent ) that target multiple underlying factors of AMD A61K 38 / 17 ( 2006 .01 ) ( e .
    [Show full text]
  • Aldrich Raman
    Aldrich Raman Library Listing – 14,033 spectra This library represents the most comprehensive collection of FT-Raman spectral references available. It contains many common chemicals found in the Aldrich Handbook of Fine Chemicals. To create the Aldrich Raman Condensed Phase Library, 14,033 compounds found in the Aldrich Collection of FT-IR Spectra Edition II Library were excited with an Nd:YVO4 laser (1064 nm) using laser powers between 400 - 600 mW, measured at the sample. A Thermo FT-Raman spectrometer (with a Ge detector) was used to collect the Raman spectra. The spectra were saved in Raman Shift format. Aldrich Raman Index Compound Name Index Compound Name 4803 ((1R)-(ENDO,ANTI))-(+)-3- 4246 (+)-3-ISOPROPYL-7A- BROMOCAMPHOR-8- SULFONIC METHYLTETRAHYDRO- ACID, AMMONIUM SALT PYRROLO(2,1-B)OXAZOL-5(6H)- 2207 ((1R)-ENDO)-(+)-3- ONE, BROMOCAMPHOR, 98% 12568 (+)-4-CHOLESTEN-3-ONE, 98% 4804 ((1S)-(ENDO,ANTI))-(-)-3- 3774 (+)-5,6-O-CYCLOHEXYLIDENE-L- BROMOCAMPHOR-8- SULFONIC ASCORBIC ACID, 98% ACID, AMMONIUM SALT 11632 (+)-5-BROMO-2'-DEOXYURIDINE, 2208 ((1S)-ENDO)-(-)-3- 97% BROMOCAMPHOR, 98% 11634 (+)-5-FLUORODEOXYURIDINE, 769 ((1S)-ENDO)-(-)-BORNEOL, 99% 98+% 13454 ((2S,3S)-(+)- 11633 (+)-5-IODO-2'-DEOXYURIDINE, 98% BIS(DIPHENYLPHOSPHINO)- 4228 (+)-6-AMINOPENICILLANIC ACID, BUTANE)(N3-ALLYL)PD(II) CL04, 96% 97 8167 (+)-6-METHOXY-ALPHA-METHYL- 10297 ((3- 2- NAPHTHALENEACETIC ACID, DIMETHYLAMINO)PROPYL)TRIPH 98% ENYL- PHOSPHONIUM BROMIDE, 12586 (+)-ANDROSTA-1,4-DIENE-3,17- 99% DIONE, 98% 13458 ((R)-(+)-2,2'- 963 (+)-ARABINOGALACTAN BIS(DIPHENYLPHOSPHINO)-1,1'-
    [Show full text]
  • Triptans Step Therapy/Quantity Limit Criteria
    Triptans Step Therapy/Quantity Limit Criteria Program may be implemented with the following options 1) step therapy 2) quantity limits or 3) step therapy with quantity limits For Blue Cross and Blue Shield of Illinois Option 1 (step therapy only) will apply. Brand Generic Dosage Form Amerge® naratriptan tablets Axert® almotriptan tablets Frova® frovatriptan tablets Imitrex® sumatriptan injection*, nasal spray, tablets* Maxalt® rizatriptan tablets Maxalt-MLT® rizatriptan tablets Relpax® eletriptan tablets Treximet™ sumatriptan and naproxen tablets Zomig® zolmitriptan tablets, nasal spray Zomig-ZMT® zolmitriptan tablets * generic available and included as target agent in quantity limit edit FDA APPROVED INDICATIONS1-7 The following information is taken from individual drug prescribing information and is provided here as background information only. Not all FDA-approved indications may be considered medically necessary. All criteria are found in the section “Prior Authorization Criteria for Approval.” Amerge® Tablets1, Axert® Tablets2, Frova® Tablets3,Imitrex® injection4, Imitrex Nasal Spray5, Imitrex Tablets6, Maxalt® Tablets7, Maxalt-MLT® Tablets7, Relpax® Tablets8, Treximet™ Tablets9, Zomig® Tablets10, Zomig-ZMT® Tablets10, and Zomig® Nasal Spray11 Amerge (naratriptan), Axert (almotriptan), Frova (frovatriptan), Imitrex (sumatriptan), Maxalt (rizatriptan), Maxalt-MLT (rizatriptan orally disintegrating), Relpax (eletriptan), Treximet (sumatriptan/naproxen), Zomig (zolmitriptan), and Zomig-ZMT (zolmitriptan orally disintegrating) tablets, and Imitrex (sumatriptan) and Zomig (zolmitriptan) nasal spray are all indicated for the acute treatment of migraine attacks with or without aura in adults. They are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. Safety and effectiveness of all of these products have not been established for cluster headache, which is present in an older, predominantly male population.
    [Show full text]
  • United States Patent (19) (11) 4,232,002 Nogrady 45) Nov
    United States Patent (19) (11) 4,232,002 Nogrady 45) Nov. 4, 1980 (54) PROCEDURES AND PHARMACEUTICAL (56) References Cited PRODUCTS FOR USE IN THE PUBLICATIONS ADMINISTRATION OF ANTHISTAMINES American Hospital Formulary Service, 1966, 4:00 Anti (75. Inventor: Stephen G. Nogrady, Sully, near histamine Drugs, Penarth, Great Britain Primary Examiner-Stanley J. Friedman Attorney, Agent, or Firm-Young & Thompson 73) Assignee: The Welsh National School of Medicine, Penarth, Great Britain 57 ABSTRACT An antihistamine of the benzhydrylether, alkylamine, or (21) Appl. No.: 965,171 benzocyloheptatiophene class is suitable for use in the therapeutic treatment or prophylaxis of reversible air (22 Filed: Nov.30, 1978 ways obstruction by inhalation. The antihistamine may be clemastine, chlorpheniramine or ketotifen and may (30) Foreign Application Priority Data be in the form of a composition in admixture with a diluent. The antihistamine can be administered from a Dec. 1, 1977 GB) United Kingdom ..................... 5.0020 pharmaceutical inhalation device which is designed to 51 Int. Cl. ......................... A61L 9/04; A61 K9/04; administer a dosage unit of the antihistamine. The inha A61K 31/44 lation device can be in the form of a pressurized aerosol 52 U.S. C. ........................................ 424/45; 424/46; inhaler or a dry powder insufflator. 424/263 58) Field of Search ............................ 424/263, 46, 45 5 Claims, No Drawings 4,232,002 1. 2 inhalation provides the equivalent of 0.1 to 5 mg. of PROCEDURES AND PHARMACEUTICAL clemastine, or 0.05 to 2.5 mg. of chlorpheniramine. The PRODUCTS FOR USE IN THE ADMINISTRATION drug may be inhaled in the form of a mist or nebulized OF ANTHISTAMINES spray, or as a cloud of fine solid particles, and may be inhaled from a variety of inhaler devices.
    [Show full text]